Investors

Invest in innovation that has the potential to transform healthcare

Company Overview

Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer – the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device.

Stock Information
Change
Volume
Market Cap
Stock Information
NASDAQLUCD
Stock Information

Latest News & Updates

Oct 9, 2024
Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced...

Oct 8, 2024
Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024

Company to showcase EsoGuard® and EsoCheck® at the conference's Innovation Pavilion NEW YORK, Oct. 8, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a...

Oct 1, 2024
Lucid Diagnostics Holds Inaugural #CheckYourFoodTube Precancer Testing Event for Former NFL Players

Initiative aims to increase awareness of the relationship between chronic heartburn and esophageal cancer, and role of EsoGuard esophageal precancer testing NEW YORK, Oct. 1, 2024 /PRNewswire/ --...

VIEW ALL NEWS